Dianthus Therapeutics, Inc. (NASDAQ:DNTH) Shares Sold by ADAR1 Capital Management LLC

ADAR1 Capital Management LLC decreased its holdings in Dianthus Therapeutics, Inc. (NASDAQ:DNTH) by 85.1% in the fourth quarter, according to the company in its most recent filing with the Securities and Exchange Commission. The fund owned 17,683 shares of the company’s stock after selling 101,055 shares during the period. ADAR1 Capital Management LLC owned approximately 0.06% of Dianthus Therapeutics worth $385,000 at the end of the most recent quarter.

Several other institutional investors and hedge funds have also recently bought and sold shares of DNTH. FMR LLC lifted its holdings in Dianthus Therapeutics by 0.8% during the 4th quarter. FMR LLC now owns 4,439,281 shares of the company’s stock worth $96,776,000 after buying an additional 36,133 shares during the last quarter. Alliancebernstein L.P. lifted its holdings in shares of Dianthus Therapeutics by 13.4% in the 4th quarter. Alliancebernstein L.P. now owns 1,159,776 shares of the company’s stock valued at $25,283,000 after buying an additional 136,633 shares during the period. Wellington Management Group LLP increased its holdings in Dianthus Therapeutics by 12.2% in the fourth quarter. Wellington Management Group LLP now owns 60,337 shares of the company’s stock valued at $1,315,000 after buying an additional 6,552 shares in the last quarter. JPMorgan Chase & Co. boosted its position in Dianthus Therapeutics by 14.0% during the fourth quarter. JPMorgan Chase & Co. now owns 12,129 shares of the company’s stock worth $264,000 after purchasing an additional 1,490 shares in the last quarter. Finally, KLP Kapitalforvaltning AS acquired a new position in shares of Dianthus Therapeutics in the fourth quarter valued at approximately $33,000. 47.53% of the stock is currently owned by hedge funds and other institutional investors.

Dianthus Therapeutics Price Performance

DNTH stock opened at $16.12 on Monday. The company has a market capitalization of $517.86 million, a P/E ratio of -6.45 and a beta of 1.62. Dianthus Therapeutics, Inc. has a 12 month low of $14.78 and a 12 month high of $32.27. The firm’s fifty day simple moving average is $21.48 and its 200-day simple moving average is $23.89.

Dianthus Therapeutics (NASDAQ:DNTH) last released its earnings results on Tuesday, March 11th. The company reported ($0.81) earnings per share (EPS) for the quarter, topping analysts’ consensus estimates of ($0.85) by $0.04. The business had revenue of $1.33 million during the quarter, compared to analyst estimates of $1.40 million. Dianthus Therapeutics had a negative net margin of 1,250.32% and a negative return on equity of 21.68%. As a group, sell-side analysts forecast that Dianthus Therapeutics, Inc. will post -2.61 earnings per share for the current year.

Wall Street Analyst Weigh In

A number of equities research analysts have weighed in on DNTH shares. Guggenheim restated a “buy” rating and set a $84.00 price objective on shares of Dianthus Therapeutics in a research note on Wednesday, March 12th. TD Cowen began coverage on shares of Dianthus Therapeutics in a report on Friday, December 20th. They issued a “buy” rating on the stock. Raymond James raised Dianthus Therapeutics to a “moderate buy” rating in a report on Thursday, December 12th. HC Wainwright reiterated a “buy” rating and set a $40.00 price objective on shares of Dianthus Therapeutics in a report on Wednesday, March 12th. Finally, Wedbush reaffirmed an “outperform” rating and issued a $36.00 target price on shares of Dianthus Therapeutics in a research report on Wednesday, March 12th. Seven equities research analysts have rated the stock with a buy rating and two have given a strong buy rating to the company. According to data from MarketBeat.com, the stock has an average rating of “Buy” and an average target price of $54.33.

About Dianthus Therapeutics

Dianthus Therapeutics, Inc, a clinical-stage biotechnology company, develops complement therapeutics for patients with severe autoimmune and inflammatory diseases. It is developing DNTH103, a monoclonal antibody, which is in Phase 2 clinical trial, for the treatment of generalized myasthenia gravis, multifocal motor neuropathy, and chronic inflammatory demyelinating polyneuropathy.